Is There a “New Normal” for Drug Quality?

With some FDA inspections on hold, will the US drug supply maintain its quality standards?

In February 2020, a report from FDA’s Office of Pharmaceutical Quality (OPQ) noted that, “Quite simply, the quality of our drug supply is better than ever before.” With some FDA inspections on hold, will the US drug supply maintain its quality standards? Plus, which new drug applications must now be filed as biologic license application?

Read this article in BioPharm International’s March 2020 Regulatory Sourcebook.

Article Details

BioPharm International
eBook: Regulatory Sourcebook and Reference, March 2020
March 2020
Pages: 4–5

Citation

When referring to this article, please cite it as R. Peters, “Is There a “New Normal” for Drug Quality?" BioPharm International Regulatory Sourcebook and Reference eBook (March 2020).

Articles in this issue

over 5 years ago

Article

Resources, Guidelines, and Guidance Documents

over 5 years ago

Article

Regulatory and Standard Setting Organizations

over 5 years ago

Article

Monograph Development: Why and When to Participate (eBook)

over 5 years ago

Article

Pharmacopoeia Compliance: Putting It All Together; What Is on the Horizon (eBook)

over 5 years ago

Article

A Practical Approach to Pharmacopoeia Compliance (eBook)

over 5 years ago

Article

Inside FDA’s New Gene and Cell Therapy Guidances

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!